Features of the Development and Application of Diagnostic ELISA Systems for the Detection of Antibodies to the SARS-CoV-2 Coronavirus in Clinical Practice

Abstract

Introduction. The new coronavirus infection, COVID-19, caused by SARS-CoV-2 has reached the scale of a pandemic. Detection of antibodies to SARS-CoV-2 is an aid in the diagnosis of COVID-19, and is also used to assess the immune response to the infection. Since COVID-19 is a new disease, seroconversions and kinetics of antibody to SARS-CoV-2 are not well understood.

The aim of the study is to evaluate seroconversions and kinetics of antibodies to SARS-CoV-2 (IgA, IgM, IgG and total) in real clinical practice using test systems of national production.

Materials and methods. 327 blood samples obtained from patients with a confirmed diagnosis of COVID-19 with active infection, convalescents and healthy donors were analyzed. Detection of antibodies to SARS-CoV-2 was carried out by enzyme immunoassay method using registered test systems “Antigma-A”, “Antigma-G”, “Antigma-Screen” and an unregistered test system for the detection of class M immunoglobulins.

Results. When testing for total antibodies, 50.0% of samples were positive on days 1-7; 89.4% on days 8-14; 96.2% on days 15-45; and 93.3% after the 46^th day after disease onset. The earliest seroconversions occurred on the 3^rd day; antibodies were detected up to 81 days after the disease onset.

Conclusions. The frequency of detecting seroconversions when using test systems of the “Antigma” series in real clinical practice is comparable to the data published in the world scientific literature and is high enough to use these test systems in the COVID-19 diagnostics.

Keywords

COVID-19 diagnostics / antibodies / IgA / IgM / IgG / “Antigma”

References

[1] Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2020;6:1–14. DOI: 10.1038/s41579-020-00459-7

[2] Hu B., Guo H., Zhou P. et al. Characteristics of SARS-CoV-2 and COVID-19 // Nat. Rev. Microbiol. 2020. No. 6. P. 1–14. DOI: 10.1038/s41579-020-00459-7

[3] Huang AT, Garcia-Carreras B, Hitchings MDT, et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nat Commun. 2020;11(1):4704. DOI: 10.1038/s41467-020-18450-4

[4] Huang A.T., Garcia-Carreras B., Hitchings M.D.T. et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity // Nat. Commun. 2020. Vol. 11, No. 1. P. 4704. DOI: 10.1038/s41467-020-18450-4

[5] Vremennye metodicheskie rekomendatsii “Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19)”. Ministerstvo zdravookhraneniya Rossiiskoi Federatsii. Versiya 9 ot 26.10.2020 g. Available from: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/052/548/original/%D0%9C%D0%A0_COVID-19_%28v.9%29.pdf?1603730062. (In Russ.)

[6] Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)» / Министерство здравоохранения Российской Федерации. Версия 9 от 26.10.2020 г. Режим доступа: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/052/548/original/ %D0 %9C %D0 %A0_COVID-19_ %28v.9 %29.pdf?1603730062

[7] Deeks JJ, Dinnes J, Takwoingi Y, et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst Rev. 2020;6(6):CD013652. DOI: 10.1002/14651858.CD013652

[8] Deeks J.J., Dinnes J., Takwoingi Y. et al. Antibody tests for identification of current and past infection with SARS-CoV-2 // Cochrane Database Syst. Rev. 2020. Vol. 6, No. 6. P. CD013652. DOI: 10.1002/14651858.CD013652

[9] Murchu EO, Byrne P, Walsh KA, et al. Immune response following infection with SARS-CoV-2 and other coronaviruses: a rapid review. Rev Med Virol. 2020;e2162. DOI: 10.1002/rmv.2162

[10] Murchu E.O., Byrne P., Walsh K.A. et al. Immune response following infection with SARS-CoV-2 and other coronaviruses: a rapid review // Rev. Med. Virol. 2020. P. e2162. DOI: 10.1002/rmv.2162

[11] Demey B, Daher N, François C, et al. Dynamic profile for the detection of anti-SARS-CoV-2 antibodies using four immunochromatographic assays. J Infect. 2020;81(2):e6–e10. DOI: 10.1016/j.jinf.2020.04.033

[12] Demey B., Daher N., François C. et al. Dynamic profile for the detection of anti-SARS-CoV-2 antibodies using four immunochromatographic assays // J. Infect. 2020. Vol. 81, No. 2. P. e6–e10. DOI: 10.1016/j.jinf.2020.04.033

[13] Hou H, Wang T, Zhang B, et al. Detection of IgM and IgG antibodies in patients with coronavirus disease 2019. Clin Transl Immunology. 2020;9(5):e01136. DOI: 10.1002/cti2.1136

[14] Hou H., Wang T., Zhang B. et al. Detection of IgM and IgG antibodies in patients with coronavirus disease 2019 // Clin. Transl. Immunology. 2020. Vol. 9, No. 5. P. e01136. DOI: 10.1002/cti2.1136

[15] La Rosa Fabián C, Urquizo Briceño L. Anti-SARS-Cov-2 IgA in current scenario of IgM and IgG rapid test: a new alternative for the diagnostic of COVID-19. SN Compr Clin Med. 2020;2:2167–2169. DOI: 10.1007/s42399-020-00551-2

[16] La Rosa Fabián C., Urquizo Briceño L. Anti-SARS-Cov-2 IgA in current scenario of IgM and IgG rapid test: a new alternative for the diagnostic of COVID-19 // SN Compr. Clin. Med. 2020. Vol. 2. P. 2167–2169. DOI: 10.1007/s42399-020-00551-2

[17] Ma H, Zeng W, He H, et al. Serum IgA, IgM, and IgG responses in COVID-19. Cell Mol Immunol. 2020;17(7):773–775. DOI: 10.1038/s41423-020-0474-z

[18] Ma H., Zeng W., He H. et al. Serum IgA, IgM, and IgG responses in COVID-19 // Cell. Mol. Immunol. 2020. Vol. 17, No. 7. P. 773–775. DOI: 10.1038/s41423-020-0474-z

[19] Yu HQ, Sun BQ, Fang ZF, et al. Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients. Eur Respir J. 2020;56(2):2001526. DOI: 10.1183/13993003.01526-2020

[20] Yu H.Q., Sun B.Q., Fang ZF. et al. Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients // Eur. Respir. J. 2020. Vol. 56, No. 2. P. 2001526. DOI: 10.1183/13993003.01526-2020

[21] Padoan A, Sciacovelli L, Basso D, et al. IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study. Clin Chim Acta. 2020;507:164–166. DOI: 10.1016/j.cca.2020.04.026

[22] Padoan A., Sciacovelli L., Basso D. et al. IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study // Clin. Chim. Acta. 2020. No. 507. P. 164–166. DOI: 10.1016/j.cca.2020.04.026

[23] Ma H, Zhao D, Zeng W, et al. Decline of SARS-CoV-2-specific IgG, IgM and IgA in convalescent COVID-19 patients within 100 days after hospital discharge. Sci China Life Sci. 2020;1–4. DOI: 10.1007/s11427-020-1805-0

[24] Ma H., Zhao D., Zeng W. et al. Decline of SARS-CoV-2-specific IgG, IgM and IgA in convalescent COVID-19 patients within 100 days after hospital discharge // Sci. China Life Sci. 2020. P. 1–4. DOI: 10.1007/s11427-020-1805-0

[25] Ni L, Ye F, Cheng ML, et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020;52(6):971–977.e3. DOI: 10.1016/j.immuni.2020.04.023

[26] Ni L., Ye F., Cheng M.L. et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals // Immunity. 2020. Vol. 52, No. 6. P. 971–977.e3. DOI: 10.1016/j.immuni.2020.04.023

[27] Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses to SARS-CoV-2 infection in convalescent individuals. bioRxiv. 2020;13:092619. DOI: 10.1101/2020.05.13.092619

[28] Robbiani D.F., Gaebler C., Muecksch F. et al. Convergent antibody responses to SARS-CoV-2 infection in convalescent individuals // bioRxiv. 2020. No. 13. P. 092619. DOI: 10.1101/2020.05.13.09261

[29] Wu F, Wang A, Liu M, et al. Neutralizing antibody responses to SARSCoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv. 2020. DOI: 10.1101/2020.03.30.20047365

[30] Wu F., Wang A., Liu M. et al. Neutralizing antibody responses to SARSCoV-2 in a COVID-19 recovered patient cohort and their implications // medRxiv. 2020. DOI: 10.1101/2020.03.30.20047365

RIGHTS & PERMISSIONS

Zagoruyko E.I., Kudlay D.A., Lysenko M.A., Fomina D.S., Vinogradov I.V., Bogachev V.V., Starostenko A.A.